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ABSTRACT  
Aims: This study investigates the antimicrobial activity and mode of action of novel 
carbohydrate fatty acid (CFA) derivatives against Staphylococcus aureus and methicillin-resistant 
Staph. aureus (MRSA). 
Methods and Results: Minimum inhibitory concentrations (MIC) and the effect of CFA 
derivatives on lag phase were determined using a broth microdilution method. Lauric acid 
carbohydrate esters and corresponding ether analogs showed the greatest antimicrobial activity 
with MIC values between 0.04 to 0.16mmol l-1. Leakage studies at 260nm following exposure to 
CFA derivatives at 4X MIC showed a significant increase in membrane permeability for all 
compounds, after ca. 15 minutes exposure except for the lauric beta ether CFA derivative. 
Further assessment using both BacLight and luminescence ATP assays, confirmed that an 
increase in membrane permeability and reduced metabolic activity was associated with CFA 
treatment.   
Conclusions: All strains were significantly inhibited by the novel compounds studied and 
efficacy was related to specific structural features. Cell-membrane permeabilization was 
associated with CFA treatment and may account for at least a component of the mode of action of 
these compounds.  
Significance and Impact of Study: This study reports the antimicrobial action of CFA 
compounds against a range of Staph. aureus and MRSA strains, and provides insights into their 
mode of action.  
 
 
Keywords: S. aureus; MRSA; Carbohydrate fatty acid derivatives; Monolaurin; Antimicrobial 
activity; Mode of action; Membrane damage 
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1. INTRODUCTION 
Staphylococcus aureus is an important human pathogen that can grow in inappropriately stored 
food causing a wide variety of diseases in humans either through toxin production or invasion. 
Staph. aureus may occur as a commensal on human skin; it can also be present in the anterior 
nares, with a mean carriage rate of 37.2% in the general population (Kluytmans et al., 1997). 
Staph. aureus is also one of the most common causes of bloodstream infection (or bacteremia) 
(Petti and Fowler, 2003).  
MRSA and antibiotic resistance is a global concern. Staph. aureus becomes methicillin 
resistant by the acquisition of the mecA gene which encodes a penicillin binding protein (PBP2a) 
with a low affinity for β-lactams, usually carried on a larger piece of DNA called a 
staphylococcal cassette chromosome SCCmec (Hartman and Tomasz, 1986). Infections caused by 
methicillin-resistant Staph. aureus (MRSA) are increasing in both hospital and community 
settings (Chopra, 2003). In Ireland there were 1,394 reports of Staph. aureus bacteraemia in 
2007, of which 537 (38.5%) were MRSA (HPSC, 2007). Consequently, there has been 
considerable interest in discovering and developing new antistaphylococcal agents for potential 
therapeutic application (Chopra, 2003).  
Carbohydrate fatty acid esters are biodegradable, non-toxic compounds currently being used 
as non-ionic surfactants in the food and health care industries. The antibacterial activity of fatty 
acid carbohydrate derivatives is increasingly of interest. Many authors have shown that these 
compounds are active against a range of pathogens (Monk et al., 1996; Yang et al., 2003; 
Devulapalle et al., 2004; Ferrer et al., 2005; Habulin et al., 2008). 
Unlike antibiotics, fatty acids and their derivatives have diverse modes of action that appear 
to be non-specific and development of resistance to these compounds has not been reported 
(Kabara and Marshall, 2005). Kitahara et al., (2006) proposed lauric acid as a potential 
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antimicrobial material, suitable for external application, which could be combined with other 
antimicrobial agents. For example, Ved et al. (1990) demonstrated that monolaurin (ML), the 
glycerol monoester of lauric acid, acted synergistically with penicillin G at concentrations below 
its minimum micelle concentration. Kitahara et al., 2006, found that a lauric acid and gentamicin 
combination showed synergistic activity against MRSA.  
The exact mode of action of CFAs on bacteria is unknown. However, it has been proposed, 
and is widely believed, that the cell membrane is the principal site of action of fatty acids and 
their esters (Kabara, 1993). Wang and Johnson (1992) found that monolaurin, a compound 
closely related to CFA esters, produced marked morphological changes in L. monocytogenes 
cells. While Bergsson et al. (2001) demonstrated that Staph. aureus was killed by fatty acids and 
derivatives, especially monocaprin, through disintegration of the cell membrane. The mechanism 
of the induction of autolysis by these types of compounds, remains to be elucidated, although it is 
suggested that they may disorganize the membrane structure and trigger an, as of yet 
unidentified, autolysin control system, possibly located in and/or on the cell membrane 
(Tsuchido, et al., 1993).  
It  has also been suggested that ML may affect the respiratory activity of cells by the 
inhibition of enzymes involved in oxygen uptake and/or inhibit the transport of amino acids into 
cells (Galbraith and Miller, 1973). Other researchers have reported that monolaurin at sub-MIC 
concentrations inhibited production of β-lactamases, toxic shock syndrome toxin 1 and other 
exoproteins in Staph. aureus at the level of transcription by interfering with signal transduction 
(Schlievert et al.,1992; Projan et al., 1994). Interference with signal transduction has been shown 
in other genera, for example, monolaurin suppressed growth of vancomycin- resistant 
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Enterococcus faecalis in the presence of vancomycin and blocked the induction of vancomycin 
resistance (Ruzin and Novick, 1998). 
A detailed study by Ruzin and Novick (2000) showed that ML inhibited the production of 
exoenzymes and virulence factors in Staph. aureus at concentrations that did not inhibit bacterial 
growth. Moreover, they were able to show rapid hydrolysis of ML with liberation of lauric acid 
(t1/2 of ~5 min) in the presence of Staph. aureus cells. These findings led them to suggest that 
the prolonged inhibitory effects associated with ML might be due to liberation of lauric acid by 
hydrolases present in the cell preparation. They were not, however, able to rule out the possibility 
that ML itself might have some inhibitory action prior to its hydrolysis. These findings raise 
important questions for fatty acid derivatives of carbohydrates. It is not clear, for example, 
whether fatty acid esters of carbohydrates are similarly hydrolysed or whether their mode of 
action might depend on such hydrolysis.   
Previous studies in this laboratory, using Listeria strains, showed that an ether analog of a 
CFA retained higher or similar antimicrobial activity to the ester derivative, indicating that the 
release of a free fatty acid was not an absolute requirement for antimicrobial activity (Nobmann 
et al., 2009).  The analysis of both ester and ether fatty acid derivatives of the same carbohydrate, 
as well as both alpha and beta configurations of the carbohydrate moiety, suggested that the 
carbohydrate moiety might also be involved in the antimicrobial activity of fatty acid derivatives 
(Nobmann et al., 2009).  
The current study assessed the antimicrobial efficacy of these novel carbohydrate fatty acid 
derivatives against a range of Staph. aureus strains, as well as further investigating the 
mechanisms of action of the range of compounds to assess relationships between the defined 
structural differences and the mode of action.  Antimicrobial efficacy was evaluated by 
comparison of MIC and effects on cell lag time, while more detailed studies on how the 
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compounds might work included membrane permeability studies monitoring absorbance at 
260nm, BacLight live/dead assay and cell viability using BacTiter Glo assay. 
 
2. MATERIALS AND METHODS 
2.1 Bacteria and culture conditions 
Bacterial strains used in this study are listed in Table 1. Stock cultures were maintained in tryptic 
soy broth (TSB, Scharlau Chemie, Spain) supplemented with 20% glycerol at -70°C. For use in 
experiments, working cultures were grown routinely by subculturing a loop full of stock culture 
into TSB tubes and incubating at 35°C for 18 h.  
2.2 Test compounds  
Lauric acid (LA), caprylic acid (CA), and their corresponding monoglycerides, monolaurin (ML) 
and monocaprylin (MC) (Sigma-Aldrich ~99% purity), were used as standards for comparison 
against the CFA derivatives. Nisin, from Lactococcus lactis 2.5% (≥1.000.000 per IU/g), was 
purchased from Sigma, and was used as a positive control compound for membrane disruption 
studies. Carbohydrate fatty acid derivatives used in this study (Figure 1) were synthesized 
according to Smith et al., 2008. Stock solutions (100 mmol l-1) of test compounds (CFA 
derivatives and standards) were prepared in sterile hydroalcoholic diluent (ethanol-distilled water, 
1:1) and stored at -20°C. Stock solutions were diluted in TSB or phosphate-buffered saline 
solution (PBS; pH 7.4, Sigma) to obtain working concentrations.  
2.3 Minimal inhibitory concentration (MIC) 
MICs were determined using a broth microdilution assay as previously described (Nobmann et 
al., 2009). Briefly, serial dilutions of each compound were prepared in sterile TSB to a final 
volume of 100µl in 96-well microtiter plates (Sarstedt Ltd.). Each well was inoculated with 100µl 
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of the test organism in TSB to a final concentration of approximately 1x106 cfu ml-1. The MIC 
was taken as the lowest concentration of test compound at which growth was inhibited after 24 h 
of incubation at 35°C. Controls included: a) uninoculated media without test compound to assess 
changes in the media; b) uninoculated media containing the test compound to assess background 
noise; c) inoculated media without test compound to evaluate the microbial growth under optimal 
conditions; d) inoculated media without test compound but containing corresponding amount of 
ethanol to account for a possible antagonist or synergistic activity of the alcohol used in the 
preparation of the test compound. 
2.4 Increase in Lag time (∆λ) 
The increase in Lag time was calculated using data from absorbance based broth microdilution 
assays using Gen5TM software. The ∆λ was defined as the time required for the culture with test 
compound to record an increase in OD600 of 0.10 minus the time that the culture without 
compound, took to reach the same increase in OD600. 
2.5 Effect of antimicrobial compounds on the cell membrane 
For the mode of action studies, the laurate glucopyranoside derivatives (compound 1 to 4) were 
selected. These are a closely related group of compounds which differ by a single structural 
variable, and were evaluated in order to asses relationships between structural differences e.g. 
glycoconjugate linkage and anomeric configuration and antimicrobial efficacy. 
2.5.1 Leakage of 260-nm-absorbing material  
Bacterial strains were cultured in TSB and incubated at 35°C for 18 h. After incubation, bacteria 
were harvested by centrifugation at 10,000 g for 10 min at 4°C, the supernatant was discarded 
and the cells were washed twice with PBS; pH 7.4. Suspensions were adjusted to achieve a 
bacterial concentration of approximately 109 cfu ml-1. The CFA derivatives were added to 
bacterial suspensions at 4X MIC. Suspensions were incubated in a water bath at 35°C. Samples 
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of 1.5 ml were removed at time 0, and after 15, 30, 45, 60 and 120 minutes; centrifuged at 10,000 
g for 10 minutes at 4°C. 200 µl of supernatant for each treatment was added to the wells of a 96-
well plate (UV–transparent flat-bottom microplates, Costar Cat. No. 3635) and absorbance values 
at 260 nm were recorded using a UV spectrophotometer (Synergy HT, Bio-Tek). The following 
controls were included: a bacterial suspension in sterile PBS without antimicrobial agents as the 
negative control; a fatty acid control (inoculated PBS containing LA); a positive control: Nisin 
and finally a monoglyceride control: Monolaurin. Where applicable, independent readings were 
also taken, in the presence of antibacterial agents only, to enable corrections for background 
contributions. 
2.5.2 Modified Live/Dead BacLight assay  
The Live/Dead® BacLight viability kit from Molecular Probes, Inc. (Eugene, Oreg.) was used as 
described by Hilliard et al., (1999). In this assay, the SYTO-9 and propidium iodide stains 
compete for binding to the bacterial nucleic acid. SYTO-9 labels cells with both damaged and 
intact membranes, whereas propidium iodide penetrates only cells with damaged membranes.  
A culture of Staph. aureus ATCC 25923 as a model organism was grown to late log phase in 
30 ml of TSB. 25 ml of the bacterial culture were concentrated by centrifugation at 10,000 g for 
10 minutes. The supernatant was removed and the pellet was washed once in filter-sterilized 
distilled water and resuspended to 1/10th of the original volume and then diluted 1:20 into either 
sterile de-ionized water (for live bacteria estimation), 70% isopropyl alcohol (for dead bacteria 
estimation) or sterile de-ionized water containing test compounds at 4x MIC.  
Different proportions of the live and dead cells were mixed to obtain cell suspensions 
containing five different ratios, i.e. 100:0, 75:25, 50:50, 25:75 and 0:100 (in %), of live and dead 
cells for a data set to provide a standard curve.  
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Bacterial and treatment suspensions were incubated at room temperature for one hour. At the 
end of the incubation period, the suspensions were centrifuged at 10,000 g for 10 min, washed 
once in sterile de-ionized water, and resuspended to achieve 2×107 bacteria ml-1.  
A volume of 100 µl of each bacterial or treatment suspension was added in triplicate into 
separate wells of a 96-well microplate (Nunc, black). A 1X stain solution was prepared mixing 
component A (3.34 mmol l-1 SYTO 9 dye) and component B (20 mmol l-1 propidium iodide) in 
equal proportion. 100 µl of 1X stain solution was then added to each well, and the plate was 
incubated in the dark for 15 min at room temperature. At the end of the incubation period, with 
the excitation wavelength at 485 nm, the fluorescence intensity of SYTO-9 was measured at 530 
nm (emission 1; Green) for each well. With the excitation wavelength still centered at 485 nm, 
the fluorescence intensity of propidium iodide was measured at 630 nm (emission 2; Red) for 
each well of the entire plate. The Green/Red (G/R) ratio was obtained by dividing the 
fluorescence intensity of the stained bacterial suspensions (F cell) at emission 1 by the 
fluorescence intensity at emission 2. 
G/R Ratio = F cell, emission1/F cell, emission 2 
The Ratio G/R was plotted versus percentage of live cells in the Staph. aureus suspension. 
2.5.3 BacTiter-Glo™ assay. 
The BacTiter-Glo™ Microbial Cell Viability assay is a method for determining the number of 
viable bacterial cells in a culture based on quantifying the ATP present, as an indicator of 
metabolic activity. The luminescent signal is proportional to the amount of ATP present, which is 
directly proportional to the number of cells in culture. 
An overnight culture of Staph. aureus ATCC 25923 in Mueller Hinton (MH) broth was 
diluted 100-fold in fresh MH broth and used as inoculum. CFA derivatives were used at a 
concentration of 4X MIC. Each well of a 96-well microtiter plate contained 100µl of the 
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inoculum and 100µl of the CFA derivatives. Control wells containing medium without cells were 
prepared to obtain a value for background luminescence. Cells without compound were used as 
an ATP positive control. The microtiter plate was incubated at 35°C for 5 hours. One hundred 
microliters of the culture was taken from each well, and mixed with the same volume of the 
BacTiter-Glo™ reagent in a white opaque-walled microtiter plate (Nunc). Plates were incubated 
for five minutes and luminescence was recorded in a multi-detection microplate reader (Synergy 
HT, Bio-Tek).  
2.6 Statistical analysis 
All experiments were performed in duplicate and replicated at least three times. Statistical 
differences between compound efficacies were determined using ANOVA followed by LSD 
testing at p < 0.05 level using SPSS software, Version 15. 
 
3. RESULTS  
3.1 Minimum inhibitory concentration 
The MICs of the CFA derivatives for the five S. aureus strains tested are shown in Table 2. The 
concentration of ethanol in the control wells corresponding to the concentration of ethanol in the 
test wells had no independent inhibitory effect on bacterial growth. Caprylic acid was the least 
effective of all compounds tested (p < 0.05), with MICs of 10 mmol l-1 or greater for all bacteria. 
In contrast, lauric acid had MICs eight- to 16-fold lower than those of caprylic acid. Monolaurin 
and monocaprylin showed greater activity (p<0.05), with values between 0.04-0.08 mmol l-1 and 
2.5-5 mmol l-1 respectively, than their corresponding free fatty acids (LA, CA) with values 
between 0.63-1.25 mmol l-1 and 10-20 mmol l-1. Compounds 2 (α-glucose lauric ether), 3 (β-
glucose lauric ester) and 6 (α-mannose lauric ester) were the most active carbohydrate fatty acid 
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derivatives with MIC values between 0.04-0.16 mmol l-1, comparable to ML (Table 2). The next 
in order of overall efficacy was compound 1 (α-glucose lauric ester), with MICs between 0.08 
mmol l-1 and 1.25 mmol l-1 with a difference between strains observed. The antimicrobial activity 
of compound 4 (β-glucose lauric ether) was significantly lower than that observed with the 
corresponding α-glucose lauric ether (compound 2, p < 0.05), but additionally for compound (4) 
in particular, strain differences were observed (Table 2). Compound 5 had an activity comparable 
to MC. 
3.2 Increase in Lag time for Staph. aureus 
Where appropriate, the increase in lag time was estimated for Staph. aureus ATCC 25923 in the 
presence of a range of CFA derivatives. For the concentrations at which the compounds were less 
effective (sub MIC concentrations), an increase in the lag time could be calculated to allow 
comparison between compounds and concentrations. The effect was found to be concentration 
and compound dependent, with a major effect at concentrations close to the MIC values (Table 3) 
(p < 0.05). For example, at 2-fold sub-MIC concentrations, the fatty acids (LA, CA) and 
monoglycerides (ML, MC) standards, as well as compound 1 and compound 5, showed a 
significant increase in lag time of approximately two to six hours compared to that of the cultures 
without treatment. At a 4-fold sub-MIC concentration, a relatively small increase was observed. 
For compound 4, a different trend was detected, with a more gradual increase in lag time with an 
effect observed even at 8-fold sub-MIC concentrations (from 1.25 to 0.16 mmol l-1).  
3.3 Leakage of material absorbing at 260nm  
Nucleic acid and its related compounds, such as pyrimidines and purines, absorb UV light at a 
wavelength of 260 nm. The presence of these materials in a suspension may be used as an 
indicator of damage to the cell membrane. Leakage was determined using nisin as a control, a 
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compound that is known to cause membrane damage. Table 4 shows the increase of OD260 for all 
the strains and compounds tested after 120 min of exposure. The five bacterial strains showed 
similar patterns in their release of material absorbing at 260 nm. The amount of UV absorbing 
substances released increased as the time of exposure increased, when S. aureus suspensions 
were treated with nisin, LA, ML and CFA derivatives at 4x MIC. The OD260 increased rapidly at 
first, and the absorbance values continued to increase, but more gradually after 60 minutes. An 
exception was observed for compound 4, β-glucose lauric ether, which even after 120min of 
exposure did not display a significant increase in OD260 nm. 
3.4 Live/Dead BacLight assay 
Bacterial membrane damage was further assessed by using the Live/Dead® BacLight viability 
assay. The fluorescence intensities of the stained bacterial suspension at 535nm (G, green) and 
615nm (R, red) represent live and dead cells, respectively. The fluorescence G/R ratio, obtained 
by dividing the green and red intensities, were plotted against the live:dead cells ratio used for the 
standard curve. Results are shown in Table 5. 
Exposure of staphylococcal cells to CFA derivatives (at 4x MIC for one hour) showed altered 
cytoplasmic membrane permeability for lauric acid and the alpha compounds.  Both alpha lauric 
ester (compound 1) and the alpha lauric ether (compound 2), had a low fluorescence ratio, 
corresponding to 10-20% viability compared to the untreated control.  
On the other hand, the beta lauric ester (compound 3) derivative showed a higher 
fluorescence ratio, corresponding to retention of approximately 75% viability.  The beta ether 
derivative (compound 4) did not significantly affect the fluorescence ratio, which was in 
agreement with the observation for the leakage studies at 260nm for this compound. 
3.5 BacTiter Glo assay 
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The luminescence signal is proportional to the amount of ATP present, which is directly 
proportional to the number of metabolically active cells in the culture. The results are shown in 
Figure 2.  The alpha lauric derivatives (compounds 1 and 2) resulted in a noticeable decrease in 
ATP levels. For the lauric acid and the beta derivatives (compounds 3 and 4), there was also a 
decline in ATP detected, but to a lesser extent than that observed with the alpha lauric 
derivatives. Again, this reinforces the importance of the anomeric configuration in antimicrobial 
efficacy.    
 
4. DISCUSSION 
The emergence of methicillin-resistant Staph. aureus (MRSA), vancomycin-resistant enterococci 
(VRE), and extended spectrum β-lactamase-producing Enterobacteriaceae has seriously reduced 
the number of empirical agents suitable for selected indications (Isturiz, 2008). Natural products, 
either as pure compounds or as standardized extracts, may provide opportunities for new drug 
leads because of the unmatched availability of chemical diversity (Cos et al., 2006).  
Previous work in this laboratory showed that novel CFA derivatives were active against Gram 
positive bacteria, especially the foodborne pathogen L. monocytogenes (Nobmann et al., 2009). 
Thus the present study evaluated the antimicrobial properties of pure novel carbohydrate fatty 
acid esters and their corresponding ether analogs, against five Staph. aureus strains including 
MRSA strains.  
Ruzin and Novik, (2000) showed that monolaurin was rapidly hydrolysed (t1/2 of ~5 min) by 
esterases in Staph. aureus cultures suggesting that inhibitory activity could be due to free fatty 
acid liberated from monolaurin by hydrolysis. Isaacs and Lamp (2000) suggested that changing 
the linkage in a monoglyceride between the fatty acid and the glycerol backbone from an ester 
 14 
bond to an ether linkage could increase the antimicrobial activity of some medium-chain 
monoglycerides. Here, we have examined antimicrobial activity using pure CFA derivatives 
whose carbohydrate moieties were effectively “locked” in either the alpha or beta configuration. 
These compounds also differed in the type of fatty acid carbohydrate linkage (ester and ether 
conjugates), and the length of fatty acid chain (lauric and caprylic acid).  
The CFA derivatives showed various antimicrobial activities against a panel of Gram-positive 
bacteria. In the data presented here we show that there is little difference in antibacterial activity 
between a fatty acid derivative of alpha methyl glucoside whether the linkage is via an ester or an 
ether bond (compound 1 and 2). This finding suggests that the hydrolysis of the bond between the 
fatty acid and the carbohydrate is not required for antimicrobial activity, as the ether linkage is 
not readily hydrolysed by esterases. However, an alternative explanation whereby the 
antimicrobial activity of the fatty acid ether derivative is due to binding at a site different to that 
of the ester derivative cannot be discounted. This explanation would, however, have to postulate 
two sites of action for these compounds, both equally bactericidal, which seems unlikely.  
What is surprising is that antimicrobial activity is not sensitive to the presence or absence of 
the bulky carbohydrate group but is sensitive to the configuration of the anomeric carbon of the 
carbohydrate moiety. Despite their similarity in structure, compound 2 (α-glucose lauric ether), 
was far more active against most Staph. aureus strains than compound 4 (β-glucose lauric ether). 
This observation is in agreement with Watanabe et al. (2000) who found that configuration of the 
hydroxyl group in the carbohydrate moiety markedly affected the antibacterial activity.  
The study of lag time increase showed that sub-MIC concentrations of CFAs can modify 
bacterial growth significantly. Antimicrobial efficacy of compound 4 was considerably lower 
than that of the other derivatives, nevertheless, these results show that there is a significant effect 
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of this compound on bacterial growth, even at sub-MIC concentrations. This is important in light 
of its potential combination with other antimicrobials for optimization of application of CFA 
derivatives. It is also possible that these antimicrobial agents might also work synergistically with 
certain antibiotics as has been previously reported by Ved et al., (1990), who showed that 
dodecylglycerol and penicillin G acted synergistically to decrease the MIC of both compounds 
towards Gram positive bacteria. Haynes et al. (1994) observed that the alkyl glycerol, ether rac-1-
O-dodecylglycerol, inhibited the growth of members of two genera of yeasts, Candida and 
Cryptococcus, and was strongly synergistic with amphotericin B. Similarly, Rouse et al., (2005) 
demonstrated that mupirocin and monolaurin formulations were active in vitro against Staph. 
aureus. Preuss et al.(2005), found that Origanum oil, carvacrol, and other essential oils, 
combined with monolaurin killed Staph. aureus in vitro, and proposed that origanum and/or 
monolaurin, alone or combined with antibiotics, might prove useful in the prevention and 
treatment of severe bacterial infections.  
All of the CFA derivatives studied here, except for compound 4, had the ability to affect the 
cytoplasmic membrane of Staph. aureus as judged by  the leakage of 260-nm-absorbing material 
assay and the BacLight Live/Dead fluorescence assay; however, derivatives with different 
structures had different concentration-activity profiles.  
In contrast to the leakage at 260nm and the BacLight data, that indicated no membrane 
damage, compound 4 appreciably had an effect on bacterial growth as seen by the increase in lag 
time and decrease of ATP levels, suggesting that this compound could have a different 
mechanism of action than membrane damage. The BacLight Live/Dead fluorescence and the 
ATP luminescence assays focus on the viability of the microorganism, but from different 
perspectives, the first one assesses the permeability of the cell membrane and the second one 
involves the metabolic state of the cell. For example, compound 3, which had a high 
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antimicrobial activity, showed low ability to permeabilize the membrane according to the 
Live/Dead fluorescence assay, but showed a decrease in the metabolic activity according to the 
ATP luminescence assay. These results suggest that the CFA derivatives might have different 
mechanisms or sites of action that do not only involve membrane damage. 
All CFA derivatives had an effect on methicillin-resistant Staph. aureus to an extent similar 
to that of the nonresistant strains, suggesting that the mechanisms of methicillin resistance did not 
affect the CFA derivatives efficacy.  
 
5. CONCLUSIONS 
A range of CFA derivatives were shown to have useful antimicrobial activity against Staph. 
aureus strains, with compound efficacy related to structural differences.  Carbohydrate anomeric 
configuration and fatty acid chain length have significant effects on anti-microbial efficacy.  
Carbohydrate fatty acid derivatives had the ability to affect the cytoplasmic membrane of Staph. 
aureus and MRSA strains and may account for at least a component of the mode of action of 
these compounds. Further insight into the mechanism of action will aid in the production of CFA 
derivatives as possible future therapeutic antimicrobial compounds. 
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Table 1. Staphylococcus aureus strains used in this study. 
Strain Reference  Source / Comments 
Staph. aureus ATCC 25923 clinical isolate 
Staph. aureus NCTC 1803 mammal, ovine gangrenous mastitis 
Staph. aureus ATCC 33591 Methicillin resistant 
Staph. aureus ATCC 33592 Blood, Gentamicin- and methicillin-resistant 
Staph. aureus ATCC 43300 clinical isolate, F-182, Methicillin- and oxacillin-resistant 
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Table 2. Minimum Inhibitory Concentration (MIC) values of CFA derivatives and standards. 
Fatty acid Monoglyceride  Carbohydrate fatty acid derivatives 
Microorganism LA CA ML MC  1 2 3 4 5 6 
S. aureus  
ATCC 25923 0.63 10 0.04 5  0.31 0.04 0.04 2.5 2.5 0.04 
S. aureus  
NCTC 1803 0.63 10 0.04 2.5  0.31 0.04 0.08 1.25 1.25 0.04 
S. aureus  
ATCC 33591 1.25 10 0.04 2.5  1.25 0.04 0.04 2.5 5 0.04 
S. aureus  
ATCC 33592 1.25 20 0.04 2.5  0.08 0.08 0.04 5 2.5 0.16 
S. aureus  
ATCC 43300 1.25 10 0.08 2.5  0.08 0.08 0.04 10 2.5 0.08 
MIC was recorded as the concentration (mmol l-1) that resulted in total inhibition of all replicates after 24h at 35°C. 
LA: Lauric acid; CA: Caprylic acid; ML: Monolaurin; MC: Monocaprylin 1. Methyl 6-O-lauroyl-α-D-
glucopyranoside; 2. Methyl 6-O-dodecanyl-α-D-glucopyranoside; 3. Methyl 6-O-lauroyl-β-D-glucopyranoside; 4. 
Methyl 6-O-dodecanyl-β-D-glucopyranoside; 5. Methyl 6-O-octanoyl-α-D-glucopyranoside; 6. Methyl 6-O-lauroyl-
α-D-mannopyranoside 
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Table 3. Increase in Lag time (∆λ) for Staph. aureus ATCC 25923 in the presence of standards 
and CFA derivatives. 
∆ λ 
(h) SD
∆ λ 
(h) SD
LA 0.04 0.0 ± 0.000 CA 0.63 0.0 ± 0.000
0.08 0.0 ± 0.000 1.25 0.2 ± 0.009
0.16 0.5 ± 0.364 2.5 0.6 ± 0.221
0.31 4.2 ± 0.898 5 3.0 ± 0.312
0.63 N.G 10 N.G
ML 0.02 3.9 ± 0.684 MC 1.25 0.0 ± 0.000
0.04 N.G 2.5 1.8 ± 0.986
5 N.G
1 0.04 0.0 ± 0.000 5 0.63 0.5 ± 0.327
0.08 0.7 ± 0.167 1.25 1.3 ± 0.376
0.16 6.1 ± 0.595 2.5 N.G
0.31 N.G
4 0.16 2.7 ± 1.777
0.31 3.9 ± 2.865
0.63 4.1 ± 2.021
1.25 6.4 ± 1.615
2.5 N.G
Compound 
(mmol l-1)
Compound 
(mmol l-1)
S. aureus  ATCC 25923
 
Values are expressed as the difference between the treated culture and culture without compound. SD: Standard 
deviation. N.G.: No growth. LA: Lauric acid; CA: Caprylic acid; ML: Monolaurin; MC: Monocaprylin; 1. Methyl 6-
O-lauroyl-α-D-glucopyranoside; 4. Methyl 6-O-dodecanyl-β-D-glucopyranoside; 5. Methyl 6-O-octanoyl-α-D-
glucopyranoside. 
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Table 4. Effects of CFAs at 4x MIC on membrane integrity in S. aureus strains measured by release of UV absorbing components at 260 nm. 
Carbohydrate fatty acid derivatives Organism Time (mins) 
Negative  
control 
Positive 
control (Nisin) 
Free fatty acid 
(Lauric acid) 
Monoglyceride 
(Monolaurin) 1 2 3 4 
S. aureus 0 0 SD 0 SD 0 SD 0 SD 0 SD 0 SD 0 SD 0 SD 
ATCC 15 0.019 ±0.006 0.169 ±0.054 0.120 ±0.005 0.180 ±0.088 0.107 ±0.021 0.106 ±0.029 0.149 ±0.046 0.037 ±0.033 
25923 30 0.033 ±0.019 0.257 ±0.055 0.214 ±0.078 0.201 ±0.042 0.155 ±0.021 0.155 ±0.020 0.220 ±0.082 0.045 ±0.027 
 45 0.050 ±0.031 0.321 ±0.061 0.264 ±0.038 0.226 ±0.043 0.208 ±0.039 0.189 ±0.013 0.299 ±0.036 0.056 ±0.037 
 60 0.098 ±0.062 0.410 ±0.080 0.255 ±0.024 0.272 ±0.078 0.240 ±0.037 0.234 ±0.033 0.315 ±0.074 0.062 ±0.040 
 120 0.073 ±0.004 0.396 ±0.012 0.334 ±0.040 0.291 ±0.003 0.415 ±0.010 0.355 ±0.015 0.408 ±0.031 0.088 ±0.007 
                  
S. aureus 0 0  0  0  0  0  0  0  0  
NCTC 15 0.008 ±0.009 0.023 ±0.010 0.138 ±0.005 0.144 ±0.006 0.087 ±0.009 0.058 ±0.020 0.156 ±0.005 0.001 ±0.000 
1803 30 0.029 ±0.012 0.077 ±0.006 0.176 ±0.009 0.172 ±0.009 0.164 ±0.082 0.141 ±0.029 0.204 ±0.008 0.004 ±0.005 
 45 0.048 ±0.001 0.166 ±0.023 0.308 ±0.001 0.344 ±0.004 0.267 ±0.016 0.210 ±0.021 0.289 ±0.021 0.018 ±0.004 
 60 0.049 ±0.002 0.190 ±0.013 0.239 ±0.020 0.267 ±0.005 0.277 ±0.009 0.254 ±0.001 0.274 ±0.002 0.003 ±0.004 
 120 0.084 ±0.009 0.256 ±0.011 0.288 ±0.068 0.309 ±0.008 0.323 ±0.012 0.316 ±0.019 0.305 ±0.006 0.001 ±0.000 
                  
S. aureus 0 0  0  0  0  0  0  0  0  
ATCC 15 0.007 ±0.004 0.127 ±0.006 0.073 ±0.012 0.125 ±0.039 0.083 ±0.046 0.065 ±0.005 0.110 ±0.012 0.006 ±0.006 
33591 30 0.016 ±0.014 0.152 ±0.036 0.066 ±0.010 0.162 ±0.033 0.138 ±0.069 0.127 ±0.020 0.155 ±0.050 0.013 ±0.013 
 45 0.040 ±0.007 0.198 ±0.050 0.149 ±0.016 0.204 ±0.060 0.163 ±0.072 0.191 ±0.027 0.287 ±0.110 0.043 ±0.034 
 60 0.047 ±0.046 0.239 ±0.100 0.095 ±0.045 0.311 ±0.114 0.219 ±0.102 0.233 ±0.076 0.315 ±0.131 0.036 ±0.040 
 120 0.033 ±0.003 0.244 ±0.019 0.073 ±0.005 0.439 ±0.007 0.248 ±0.004 0.206 ±0.013 0.270 ±0.010 0.015 ±0.003 
                  
S. aureus 0 0  0  0  0  0  0  0  0  
ATCC 15 0.011 ±0.009 0.101 ±0.013 0.137 ±0.017 0.178 ±0.055 0.187 ±0.074 0.162 ±0.042 0.266 ±0.071 0.019 ±0.023 
33592 30 0.032 ±0.032 0.164 ±0.006 0.180 ±0.051 0.264 ±0.021 0.278 ±0.081 0.228 ±0.050 0.315 ±0.037 0.049 ±0.034 
 45 0.043 ±0.043 0.206 ±0.011 0.134 ±0.014 0.275 ±0.001 0.342 ±0.013 0.266 ±0.004 0.372 ±0.008 0.002 ±0.012 
 60 0.043 ±0.043 0.249 ±0.006 0.201 ±0.028 0.290 ±0.017 0.344 ±0.078 0.303 ±0.044 0.419 ±0.015 0.015 ±0.038 
 120 0.096 ±0.096 0.352 ±0.127 0.237 ±0.008 0.314 ±0.038 0.399 ±0.070 0.352 ±0.053 0.473 ±0.069 0.013 ±0.022 
                  
S. aureus 0 0  0  0  0  0  0  0  0  
ATCC 15 0.010 ±0.007 0.109 ±0.005 0.135 ±0.002 0.352 ±0.006 0.180 ±0.083 0.138 ±0.068 0.160 ±0.057 0.056 ±0.048 
43300 30 0.031 ±0.019 0.180 ±0.011 0.167 ±0.003 0.488 ±0.009 0.323 ±0.114 0.265 ±0.092 0.314 ±0.085 0.047 ±0.037 
 45 0.030 ±0.003 0.242 ±0.020 0.225 ±0.012 N.D  0.336 ±0.004 0.255 ±0.009 0.336 ±0.002 0.020 ±0.006 
 60 0.029 ±0.006 0.248 ±0.043 0.236 ±0.006 0.528 ±0.002 0.422 ±0.096 0.343 ±0.045 0.411 ±0.068 0.042 ±0.035 
 120 0.050 ±0.031 0.289 ±0.130 0.416 ±0.044 0.542 ±0.009 0.507 ±0.036 0.415 ±0.027 0.494 ±0.036 0.039 ±0.040 
1. Methyl 6-O-lauroyl-α-D-glucopyranoside; 2. Methyl 6-O-dodecanyl-α-D-glucopyranoside; 3. Methyl 6-O-lauroyl-β-D-glucopyranoside; 4. Methyl 6-O-dodecanyl-β-D-
glucopyranoside; 6. Methyl 6-O-lauroyl-α-D-mannopyranoside. N.D: not determined, SD: Standard Deviation 
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Table 5. Effect of CFA derivatives at 4x MIC on membrane integrity in Staph. aureus ATCC 
25923 measured by the BacLight assay. 
Antimicrobial compounds Live % SD 
None (non treated culture) 100  
Nisin (positive control) 8.36 ± 3.00 
Lauric acid 8.39 ± 1.66 
Alpha lauric ester (1) 17.38 ± 5.41 
Alpha lauric ether (2) 16.34 ± 3.13 
Beta lauric ester (3) 76.05 ± 13.62 
Beta lauric ether (4) 147.85 ± 48.93 
Values are expressed as percentage of those obtained with control cultures not exposed to the antimicrobial 
compounds. SD: Standard deviation. 1. Methyl 6-O-lauroyl-α-D-glucopyranoside; 2. Methyl 6-O-dodecanyl-α-D-
glucopyranoside; 3. Methyl 6-O-lauroyl-β-D-glucopyranoside; 4. Methyl 6-O-dodecanyl-β-D-glucopyranoside. 
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Figure 1. Structures of the novel carbohydrate fatty acid derivatives investigated for 
antimicrobial activity. 
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Figure 2. Relative luminescence activity of Staph. aureus ATCC25923 cells in response to CFA 
derivatives using the BacTiter-GloTM assay. 
Values are expressed as percentage of those obtained with control cultures not exposed to the antimicrobial 
compounds. 1. Methyl 6-O-lauroyl-α-D-glucopyranoside; 2. Methyl 6-O-dodecanyl-α-D-glucopyranoside; 3. Methyl 
6-O-lauroyl-β-D-glucopyranoside; 4. Methyl 6-O-dodecanyl-β-D-glucopyranoside. Error bars represent Standard 
deviation values of replicate experiments. 
 
 
